Parkinson’s Disease

April 13th, 2010 |

The U.S. Food and Drug Administration (FDA) is evaluating clinical effort data that has been gathered from the take Stalevo, which is utilised for the treatment of Parkinson’s disease. The clinical effort data may declare that patients attractive the medication Stalevo could be at an increased risk for nonindustrial endocrine cancer. In the study, different drugs that are utilised to treat Parkinson’s disease (carbidopa and levodopa) were taken by patients over long-term and the results for each take were compared.

An unexpected finding in the long-term clinical effort was noted. In the trial, it was observed that patients using Stalevo had a greater probable hood of having endocrine cancer than patients attractive only the drugs carbidopa or levodopa. At this time, it is not clear whether or not Stalevo does in fact promote endocrine cancer. It is likewise early in the think to make a conclusion as to the correlation between ingest of Stalevo and endocrine cancer. Currently, the FDA’s review of Stalevo is ongoing and no new conclusions or recommendations about the ingest of this take have been made. This is an ongoing study. Earlier clinical trials that were short term did not show any correlation between endocrine cancer and the ingest of Stalevo.As with any medication; if you undergo any adverse reactions, be sure to inform your medical professional immediately. Furthermore, if you have any questions or concerns about a certain product be sure to handle this with your medical professional. If you have old a personal trauma from ingest of a medication; there are personal trauma lawyers who are available to support you protect your rights.